MOUNTAIN VIEW, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the third quarter ended September 30, 2010 after the NASDAQ Market closes on Monday, November 8, 2010.

The company will discuss financial results and provide a business update through a conference call and an audio webcast at 1:30pm PT on the same day.
 Date:   November 8, 2010 Time:   4:30 PM ET

Listen via Internet:

Schedule this webcast into MS-Outlook calendar (click open when prompted):
 Telephone:     877-359-2916 International: 224-357-2386

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA(R), which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit
CONTACT:  VIVUS, Inc.          Timothy E. Morris, Chief Financial Officer          650-934-5200          The Trout Group          Investor Relations:          Brian Korb          646-378-2923